Regeneron Pharmaceuticals, Inc. Share Price

Equities

REGN

US75886F1075

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 01/06/2024 am IST 5-day change 1st Jan Change
980.2 USD +1.06% Intraday chart for Regeneron Pharmaceuticals, Inc. -0.49% +11.60%
Sales 2024 * 1.38TCr 1,15300Cr Sales 2025 * 1.49TCr 1,24500Cr Capitalization 11TCr 8,82000Cr
Net income 2024 * 396Cr 33TCr Net income 2025 * 441.9Cr 37TCr EV / Sales 2024 * 6.99 x
Net cash position 2024 * 908.31Cr 76TCr Net cash position 2025 * 1.49TCr 1,24000Cr EV / Sales 2025 * 6.09 x
P/E ratio 2024 *
29 x
P/E ratio 2025 *
25.9 x
Employees 13,677
Yield 2024 *
-
Yield 2025 *
-
Free-Float 78.42%
More Fundamentals * Assessed data
Dynamic Chart
EMA backs approving Sanofi's Dupixent for 'smoker's lungs', FDA extends review RE
Sanofi, Regeneron's Dupixent Receives Recommendation for Approval From European Medicines Agency Committee MT
Regeneron Pharmaceuticals, Sanofi Say Dupixent FDA Application Decision Delayed by 3 Months MT
Sanofi's Dupixent Drug Review Date Extended by Three Months in the U.S. DJ
Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® for the Treatment of COPD Patients with Type 2 Inflammation CI
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,142,536, According to a Recent SEC Filing MT
Regeneron Pharmaceuticals Says GN7075 Plus Libtayo Shows Anti-Tumor Responses in Microsatellite Stable Colorectal Cancer MT
Regeneron Pharmaceuticals, Inc. Announces Positive New Results from an Ongoing Phase 1/2 Trial Evaluating its First-in-Class Costimulatory Bispecific Antibody, REGN7075 CI
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,855,489, According to a Recent SEC Filing MT
Regeneron, Sanofi Disclose Positive Results for Lung Disease Treatment Candidate MT
Jefferies Raises Regeneron Pharmaceuticals' Price Target to $1,125 From $1,115 MT
Regeneron Pharmaceuticals, Inc. and Sanofi Presents Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in the New England Journal of Medicine CI
Piper Sandler Adjusts Price Target on Regeneron Pharmaceuticals to $1,000 From $1,000.25 MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $22,355,714, According to a Recent SEC Filing MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $48,636,545, According to a Recent SEC Filing MT
More news
1 day+1.06%
1 week-0.49%
1 month+8.49%
3 months-0.27%
6 months+20.29%
Current year+11.60%
More quotes
1 week
952.30
Extreme 952.3
980.92
1 month
926.94
Extreme 926.94
997.87
Current year
871.39
Extreme 871.39
998.33
1 year
684.81
Extreme 684.805
998.33
3 years
499.78
Extreme 499.78
998.33
5 years
271.37
Extreme 271.37
998.33
10 years
269.50
Extreme 269.5
998.33
More quotes
Managers TitleAgeSince
Founder 64 08/88/08
Chief Executive Officer 71 08/88/08
Director of Finance/CFO 53 01/03/01
Members of the board TitleAgeSince
Director/Board Member 71 12/10/12
Chief Executive Officer 71 08/88/08
Director/Board Member 83 01/91/01
More insiders
Date Price Change Volume
31/24/31 980.2 +1.06% 833,169
30/24/30 969.9 +0.35% 444,018
29/24/29 966.5 -0.69% 346,743
28/24/28 973.2 -1.20% 336,857
24/24/24 985 +0.45% 259,279

Delayed Quote Nasdaq, May 01, 2024 at 01:30 am IST

More quotes
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (56.6%); - revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%); - other (3%): primarily revenues from sales of technology licenses and subcontracted research services. At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
27
Last Close Price
980.2 USD
Average target price
1,042 USD
Spread / Average Target
+6.30%
Consensus